Abiomed profit beats estimates on Impella sales
* Q1 EPS $0.08 vs est $0.03
* Q1 rev $38.8 mln vs est $37.0 mln
* Impella worldwide rev up 56 pct
* Raises FY rev outlook to $155-157 mln
Aug 2 (Reuters) - Medical device maker Abiomed Inc's quarterly profit beat analysts' expectations on higher sales of its heart pump Impella, and the company raised the low end of its full-year revenue forecast.
Worldwide revenue for Impella -- which is used to improve blood flow in heart-failure patients -- rose 56 percent to $34.7 million in the first quarter.
Abiomed now expects full-year revenue of between $155 million and $157 million as it expects worldwide Impella revenue to grow greater than 30 percent.
The company had earlier forecast full-year revenue of between $152 million and $157 million.
The company posted a first-quarter profit of $3.1 million, or 8 cents per share, compared with a loss of $4.6 million, or 12 cents per share, a year earlier.
Revenue rose 42 percent to $38.8 million.
Excluding items, it earned 16 cents per share.
Analysts on average had expected a profit of 3 cents per share, on revenue of $37 million, according to Thomson Reuters I/B/E/S.
Danvers, Massachusetts-based Abiomed's shares closed at $22.97 on Wednesday on the Nasdaq.
- Flights delayed as air pollution hits record in Shanghai
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- French launch Central African Republic mission but deaths mount
- Supreme Court to decide on patent protections for software